External link, please review our disclaimer.

NIDA Funding Strategy for Fiscal Year 2008

In accordance with the FY 2008 Congressional action and the NIH Fiscal Operations Plan for FY 08, the National Institute on Drug Abuse (NIDA) has established the following funding policy

New and Competing

NIDA will continue to use the:

New Investigators

  • NIDA is committed to supporting first-time R01 investigators (by NIH definition) and will maintain a comparable level to the average of the most recent five years. This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal payline.

Non-competing Continuations (Type 5)

  • Non-competing continuations (modular and non-modular) will be funded at 98% of committed levels, including co-funds. This policy does not apply to Fs, Ts, Ks, SBIR/STTRs, and R13s. Future year commitments will also be adjusted accordingly.
  • Awards previously issued in FY 2008 at reduced levels will be revised to restore funds to the level indicated above (see http://grants1.nih.gov/grants/guide/notice-files/NOT-OD-08-001.html).

Search for Funding

Featured Publication

Mentoring, A Guide for Drug Abuse Researchers publication cover

Mentoring: A Guide for Drug Abuse Researchers

Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site